Increase in incidence of liver diseases, surge in government and non-government awareness program, and surge in geriatric population coupled with rise in alcohol consumption and poor dietary habits have boosted the growth of the global liver disease treatment market. However, strict regulatory approvals related to liver diseases treatment drugs and vaccines and resistance to antiviral drugs used in treatment of hepatitis B and C hamper the market growth. On the contrary, presence of strong pipeline products is expected to open new opportunities for the market players in the future.
The global liver disease treatment market size was valued at $20,673.70 million in 2020, and is estimated to reach $36,455.70 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030.
Liver is one of the most important organs in the human body, since it eliminates unwanted substances from the blood, regulates chemical levels in the body, and stores nutrients for all cellular and biological activity. The phrase "liver disease" refers to a wide range of issues that cause the liver to fail to perform its primary function. Hepatitis, cirrhosis, liver cancer, and liver abscess are examples of liver diseases.
The antiviral drugs segment held the lion's share
By treatment type, the antiviral drugs segment dominated the market in 2020, accounting for more than two-fifths of the global liver disease treatment market, due to rise in prevalence of virus infected liver diseases and availability of branded and generic drugs. However, the immunosuppressants segment is projected to register the highest CAGR of 7.5% during the forecast period, owing to rise in autoimmune diseases and increase in liver transplants.
By disease type, the market is fragmented into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others (congenital hepatic fibrosis and biliary atresia). The hepatitis segment generated maximum revenue in 2020, accounting $17,337.70 million. The cancer segment is expected to witness highest CAGR of 7.80% during the forecast period.
North America accounted for a majority of the global liver disease treatment market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in consumption of alcohol, unhealthy lifestyle leading to obesity & weight gain, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, surge in liver diseases, unmet medical demands, and increase in investments in the healthcare sector in the region.
The growth of the global liver disease treatment market is attributed to increase in prevalence of liver diseases, rise in drug discovery and research, development activities for safe and effective therapies. Moreover, increase in alcohol consumption, obesity and rise in healthcare expenditure is expected to drive the market growth during the forecast years
Onkar Sumant
Manager, Healthcare at Allied Market Research
0 Comments